CN112979541B - 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用 - Google Patents
一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用 Download PDFInfo
- Publication number
- CN112979541B CN112979541B CN201911306631.5A CN201911306631A CN112979541B CN 112979541 B CN112979541 B CN 112979541B CN 201911306631 A CN201911306631 A CN 201911306631A CN 112979541 B CN112979541 B CN 112979541B
- Authority
- CN
- China
- Prior art keywords
- tumor
- compound
- cells
- sensitizer
- tumor drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 49
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 31
- -1 3-hydroxypyridine-2-carbonyl Chemical group 0.000 title claims abstract description 26
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 239000004471 Glycine Substances 0.000 title claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 153
- 239000003814 drug Substances 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 23
- 239000012528 membrane Substances 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- 239000002502 liposome Substances 0.000 claims description 18
- 239000000693 micelle Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000007853 buffer solution Substances 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 238000000502 dialysis Methods 0.000 claims description 7
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- 150000003904 phospholipids Chemical class 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000000887 hydrating effect Effects 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 229920001400 block copolymer Polymers 0.000 claims description 4
- 230000036571 hydration Effects 0.000 claims description 4
- 238000006703 hydration reaction Methods 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 claims description 3
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 230000000118 anti-neoplastic effect Effects 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 83
- 230000014509 gene expression Effects 0.000 abstract description 40
- 210000004881 tumor cell Anatomy 0.000 abstract description 32
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract description 29
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract description 29
- 230000000694 effects Effects 0.000 abstract description 23
- 229940044683 chemotherapy drug Drugs 0.000 abstract description 15
- 210000002540 macrophage Anatomy 0.000 abstract description 13
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 abstract description 10
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 abstract description 10
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 abstract description 10
- 230000000259 anti-tumor effect Effects 0.000 abstract description 9
- 230000034994 death Effects 0.000 abstract description 7
- 230000002163 immunogen Effects 0.000 abstract description 6
- 238000009169 immunotherapy Methods 0.000 abstract description 5
- 230000010287 polarization Effects 0.000 abstract description 3
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 abstract description 2
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 abstract description 2
- 102000002177 Hypoxia-inducible factor-1 alpha Human genes 0.000 abstract 1
- 230000002147 killing effect Effects 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 77
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 59
- 238000012360 testing method Methods 0.000 description 43
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 38
- 125000000217 alkyl group Chemical group 0.000 description 32
- 239000000243 solution Substances 0.000 description 24
- 229960004679 doxorubicin Drugs 0.000 description 23
- 125000003118 aryl group Chemical group 0.000 description 20
- 206010021143 Hypoxia Diseases 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 17
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 16
- 150000003839 salts Chemical class 0.000 description 16
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 230000007954 hypoxia Effects 0.000 description 12
- 229960001701 chloroform Drugs 0.000 description 10
- 229940042317 doxorubicin liposome Drugs 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 229940115080 doxil Drugs 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 229930012538 Paclitaxel Natural products 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 229940127089 cytotoxic agent Drugs 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229960001592 paclitaxel Drugs 0.000 description 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 7
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 5
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 5
- 239000010408 film Substances 0.000 description 5
- 230000001146 hypoxic effect Effects 0.000 description 5
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 5
- 229960001756 oxaliplatin Drugs 0.000 description 5
- 125000003226 pyrazolyl group Chemical group 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 4
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000002296 dynamic light scattering Methods 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102000004082 Calreticulin Human genes 0.000 description 3
- 108090000549 Calreticulin Proteins 0.000 description 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 229940127093 camptothecin Drugs 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 229960004768 irinotecan Drugs 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 125000001425 triazolyl group Chemical group 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 3
- 230000005760 tumorsuppression Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- GEZHEQNLKAOMCA-RRZNCOCZSA-N (-)-gambogic acid Chemical compound C([C@@H]1[C@]2([C@@](C3=O)(C\C=C(\C)C(O)=O)OC1(C)C)O1)[C@H]3C=C2C(=O)C2=C1C(CC=C(C)C)=C1O[C@@](CCC=C(C)C)(C)C=CC1=C2O GEZHEQNLKAOMCA-RRZNCOCZSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102000014842 Multidrug resistance proteins Human genes 0.000 description 2
- 108050005144 Multidrug resistance proteins Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 101150100944 Nos2 gene Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 101100006844 Schizosaccharomyces pombe (strain 972 / ATCC 24843) cmc4 gene Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 101100379633 Xenopus laevis arg2-a gene Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 101150088826 arg1 gene Proteins 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- KQJSQWZMSAGSHN-JJWQIEBTSA-N celastrol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@]2(C)C4=CC=C1C3=CC(=O)C(O)=C1C KQJSQWZMSAGSHN-JJWQIEBTSA-N 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- GEZHEQNLKAOMCA-UHFFFAOYSA-N epiisogambogic acid Natural products O1C2(C(C3=O)(CC=C(C)C(O)=O)OC4(C)C)C4CC3C=C2C(=O)C2=C1C(CC=C(C)C)=C1OC(CCC=C(C)C)(C)C=CC1=C2O GEZHEQNLKAOMCA-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- GEZHEQNLKAOMCA-GXSDCXQCSA-N gambogic acid Natural products C([C@@H]1[C@]2([C@@](C3=O)(C\C=C(/C)C(O)=O)OC1(C)C)O1)[C@H]3C=C2C(=O)C2=C1C(CC=C(C)C)=C1O[C@@](CCC=C(C)C)(C)C=CC1=C2O GEZHEQNLKAOMCA-GXSDCXQCSA-N 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- QALPNMQDVCOSMJ-UHFFFAOYSA-N isogambogic acid Natural products CC(=CCc1c2OC(C)(CC=C(C)C)C=Cc2c(O)c3C(=O)C4=CC5CC6C(C)(C)OC(CC=C(C)/C(=O)O)(C5=O)C46Oc13)C QALPNMQDVCOSMJ-UHFFFAOYSA-N 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000002539 nanocarrier Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- QGLWBTPVKHMVHM-KTKRTIGZSA-N (z)-octadec-9-en-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCN QGLWBTPVKHMVHM-KTKRTIGZSA-N 0.000 description 1
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 1
- 102100036509 Erythropoietin receptor Human genes 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 101150003028 Hprt1 gene Proteins 0.000 description 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000011398 antitumor immunotherapy Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000005878 benzonaphthofuranyl group Chemical group 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003034 chemosensitisation Effects 0.000 description 1
- 239000006114 chemosensitizer Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Polymers OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000005509 dibenzothiophenyl group Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 210000005008 immunosuppressive cell Anatomy 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 230000003183 myoelectrical effect Effects 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- YOZBGTLTNGAVFU-UHFFFAOYSA-N roxadustat Chemical compound C1=C2C(C)=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C1OC1=CC=CC=C1 YOZBGTLTNGAVFU-UHFFFAOYSA-N 0.000 description 1
- 229950008113 roxadustat Drugs 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- SRLOHQKOADWDBV-NRONOFSHSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] 2-(2-methoxyethoxycarbonylamino)ethyl phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)OCCOC)OC(=O)CCCCCCCCCCCCCCCCC SRLOHQKOADWDBV-NRONOFSHSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
本发明公开了一种基于N‑(3‑羟基吡啶‑2‑羰基)甘氨酸的抗肿瘤药物增敏剂及其应用。本发明具体公开的式(I)化合物可下调肿瘤细胞的PD‑L1，促进巨噬细胞由M2向M1极化，抑制吲哚胺2,3‑双加氧酶的表达，提高免疫治疗疗效；还可以降低肿瘤细胞中乏氧诱导因子‑1α的表达，下调P糖蛋白的表达，增加化疗药物对肿瘤细胞的杀伤作用，并增强细胞免疫原性死亡。本发明公开的式(I)化合物与化疗药物联用后具有显著提高的抗肿瘤效果，具有良好的应用前景。
Description
技术领域
本发明涉及医药技术领域，具体涉及N-(3-羟基吡啶-2-羰基)甘氨酸及其衍生物在制备抗肿瘤药物增敏剂中的应用。
背景技术
伴随着对肿瘤免疫学的深入研究，研究者们发现肿瘤尤其是实体肿瘤为了满足其快速生长的需要，发展成了一个由癌细胞、成纤维细胞、淋巴、血管及多种细胞外基质构成的复杂的组织结构，又称肿瘤组织微环境(TME，tumor microenviroment)。与正常组织相比，肿瘤内存在pH值相对较低、间隙压升高血管畸变、供氧不足、活性氧(ROS)升高等一系列独特的微环境特征(Microenvironmental regulation of tumor progression andmetastasis，Nature Medicine，2013，11(19)：1423；The immunosuppressive tumournetwork：myeloid-derived suppressor cells，regulatory T cells and naturalkiller T cells，Immunology，2013，2(138)：105)。肿瘤细胞新陈代谢较正常细胞更加旺盛，肿瘤组织内血管的畸形以和不均匀分布导致氧气输送受阻，最终使肿瘤内存在着大量乏氧区域(Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PASheterodimer regulated by cellular O2 tension，Proceedings of The NationalAcademy of Science of The United States of America，1995，92(12)：5510；Thetumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis，Nature，1999，6733(399)：271)。
大量研究表明肿瘤组织内乏氧与肿瘤免疫抑制微环境具有密切的联系。如肿瘤乏氧会导致M2型肿瘤相关巨噬细胞(TAM，tumor-associated macrophages)的产生，抑制肿瘤免疫反应(HIF-1 alpha is essential for myeloid cell-mediated inflammation，Cell，2003，112(5)：645-657；Hypoxia in cancer：significance and impact onclinical outcome，Cancer And Metastasis Reviews，2007，2(26)：225)。
肿瘤乏氧会抑制肿瘤浸润淋巴细胞(tumor-infiltrating lymphocytes，TIL)，尤其是杀伤性T淋巴细胞(CTL，cytotoxic T lymphocytes)的增殖和活化，进而影响效应性T细胞的功能(Obesity in C57BL/6J mice is characterized by adipose tissuehypoxia and cytotoxic T-cell infiltration，International Journal Of Obesity，2008，3(32)：451；Inhibitory effect of tumor cell-derived lactic acid on human Tcells，Blood，2007，9(109)：3812；HIF Transcription Factors，Inflammation，andImmunity，Immunity，2014，4(41)：518)。
肿瘤乏氧还会诱导癌细胞及巨噬细胞过表达PD-L1继而诱导CTL细胞的程序性死亡(A Mechanism of hypoxia-mediated escape from adaptive immunity in cancercells，Cancer Research，2014，3(74)：665；Genomic correlates of response to immunecheckpoint therapies in clear cell renal cell carcinoma，Science，2018，359(6377)：801)。
此外，肿瘤独特的微环境还会招募大量的免疫抑制型细胞，包括调节性T细胞、骨髓来源的抑制性细胞(MDSCs，myeloid-derived suppressor cells)等，这些细胞会分泌一些免疫抑制性的细胞因子，如吲哚胺2，3-双加氧酶(IDO)、过氧化氢、过氧亚硝基等活性氧/氮自由基等，进一步抑制抗原递呈细胞发挥抗原呈递的作用，从而抑制T淋巴细胞在肿瘤内的浸润、增殖与分化，不仅导致抗肿瘤免疫治疗的失败，还促进肿瘤的生长与转移(Tumormicroenvironment complexity：emerging roles in cancer therapy，Cancer Research，2012，72(10)：2473；Myeloid-derived suppressor cells：Critical cells drivingimmune suppression in the tumor microenvironment，Immunotherapy of Cancer，2015，128：95；Targeting the tumor microenvironment：removing obstruction toanticancer immune responses and immunotherapy，Annals of Oncology，2016，27(8)：1482)。因此，实体肿瘤内有别于正常组织的免疫抑制微环境特征，使得肿瘤细胞可以逃逸免疫***的攻击，这是限制肿瘤免疫治疗疗效的关键因素之一。
乏氧异质性也是会导致实体肿瘤耐药性的增加。当肿瘤体积超过31mm3时，肿瘤内部即处于乏氧状态(Intratumoral hypoxia，radiation resistance，and HIF-1，CancerCell，2004，5(5)：405)。实体肿瘤细胞在乏氧环境中对化疗药物的敏感性下降，因此乏氧是导致化疗耐药的重要因素(Molecular targeting therapy of cancer：drug resistance，apoptosis and survival signal，Cancer Science，2003，94(1)：15；Hypoxia-induciblefactor-1α contributes to hypoxia-induced chemoresistance in gastric cancer，Cancer Science，2008，99(1)：121)。此外，化疗药物治疗可进一步重构肿瘤的免疫微环境，如上调PD-L1、IDO或HIF-1α表达，使肿瘤免于自体免疫作用，进一步降低疗效。
利用免疫抑制剂逆转免疫微环境，如用PD-1/PD-L1抗体阻断肿瘤细胞对T细胞的抑制，使T细胞恢复识别和清除肿瘤细胞的功能，是目前肿瘤免疫治疗的通用方案(Theblockade of immune checkpoints in cancer immunotherapy，Nature Reviews Cancer，2012，4(12)：252；Safety，activity，and immune correlates of anti-PD-1 antibody incancer.New England Journal of Medicine，2012，26(366)：2443)，在靶点匹配的肿瘤上显示出很高的疗效。同时，化疗药物可刺激肿瘤细胞产生免疫原性死亡，诱导钙网蛋白等信号表达，吸引T细胞和树突状细胞的进入肿瘤，提高抗肿瘤免疫反应(Immunobiology ofdendritic cells.Annual Review of Immunology 2000.18：767；Cancer immunoediting：integrating immunity’s roles in cancer suppression and promotion，Science，2011，331(6024)：1565)。
因此，将某些化疗药物与PD-1/PD-L1抗体免疫检抑制剂联用可增强疗效(Adoptive immunotherapy for cancer：harnessing the T cell response，NatureReviews Immunology，2012，12(4)：269；Nishikawa H et al.，Regulatory T cells incancer immunotherapy，Current Opinion In Immunology，2014.27：1；Dendritic cellsas mediators of tumor-induced tolerance in metastatic melanoma.InternationalJournal Of Cancer.1997，73(3)：309)。但PD-1/PD-L1抗体存在着的副作用风险大、制备及储存不便、价格昂贵等问题。
N-(4-羟基-1-甲基-7-苯氧基异喹啉-3-羰基)甘氨酸(Roxadustat，ROX)通过模拟脯氨酰羟化酶(PH)的底物之一酮戊二酸来抑制低氧诱导因子的脯氨酰羟化酶，因此在正常细胞中维持甚至升高低氧诱导因子水平，不仅使红细胞生成素表达增加，也能使红细胞生成素受体以及促进铁吸收和循环的蛋白表达增加，因此在临床上作为治疗肾性贫血的药物。
发明内容
本发明提供了一种基于N-(3-羟基吡啶-2-羰基)甘氨酸及其衍生物的小分子抗肿瘤药物增敏剂，用于提高免疫和化疗***的效果。
本发明解决上述技术问题所提供的技术方案为：
本发明提供了一种抗肿瘤药物增敏剂，所述的抗肿瘤药物增敏剂为式(I)化合物或其药学上可接受的盐，
其中，
R1为H、OH、NH2、C1-20烷基、-O-C1-20烷基、-NH-C1-20烷基或-O-C6-12芳基；
R2为H、F、Cl、Br、I、OH、NH2、NO2、CN、C1-20烷基、-O-C1-20烷基、-NH-C1-20烷基、C6-12芳基、-O-C6-12芳基或5-10元杂芳基，所述的C1-20烷基、-O-C1-20烷基、-NH-C1-20烷基、C6-12芳基、-O-C6-12芳基、5-10元杂芳基任选被1、2或3个Ra取代；R3为H、F、Cl、Br、I、OH、NH2、NO2、CN、C1-20烷基、-O-C1-20烷基、-NH-C1-20烷基、C6-12芳基或-O-C6-12芳基；
R4为H、F、Cl、Br、I、OH、NH2、NO2、CN、C1-20烷基、-O-C1-20烷基、-NH-C1-20烷基、C6-12芳基、-O-C6-12芳基或5-10元杂芳基，所述的C1-20烷基、-O-C1-20烷基、-NH-C1-20烷基、C6-12芳基、-O-C6-12芳基、5-10元杂芳基任选被1、2或3个Rb取代；A环为苯基或不存在；
Ra分别独立地为F、Cl、Br、I、OH、NH2、NO2、CN、C1-3烷基或C1-3烷基苯基，所述的C1-3烷基或C1-3烷基苯基任选被1、2或3个卤素取代；
Rb分别独立地为F、Cl、Br、I、OH、NH2、NO2或CN；
m为0、1、2、3或4；
n为0、1或2。
式(I)化合物在缺氧条件下抑制脯氨酸羟化酶3(PHD3，polyl hydroylase 3)的表达，继而下调丙酮酸激酶M2(PKM2，pyruvate kinase M2)的表达，最后抑制HIF-1α的表达。伴随着HIF-1α的表达被抑制，HIF-1α与HIF-1F的二聚化程度也大大降低，使其下游因子如PD-L1、P-gp等的表达也随之降低。
式(I)化合物在肿瘤免疫治疗中的作用，包括降低肿瘤细胞PD-L1的表达，增强T淋巴细胞活性和浸润肿瘤组织；抑制吲哚胺2，3-双加氧酶表达，提高细胞毒性T细胞活性；促进巨噬细胞由M2向M1转化，逆转免疫抑制状态，并促使肿瘤细胞免疫原性死亡，增强机体对肿瘤的免疫应答，提高肿瘤免疫治疗效果。
式(I)化合物在化疗增敏中的作用，包括降低肿瘤细胞HIF-1α及多药耐药蛋白P-gp表达，抑制肿瘤的多药耐药，促进化疗药物在肿瘤细胞的内吞，提高肿瘤细胞对化疗药物敏感性从而增加化疗药物的抗肿瘤效果。
进一步的，所述的式(I)化合物为：
其中，R1、R2、R3、R4、n或m如本发明所定义。
进一步的，所述的Ra为F、Cl、Br、I、OH、NH2、NO2、CN或
进一步的，所述的R2为H、F、Cl、Br、I、OH、NH2、NO2、CN、C1-3烷基、-O-C1-3烷基、-NH-C1-3烷基、苯基、-O-苯基或吡唑基、吡咯基、吡唑基或三氮唑基，所述的C1-3烷基、-O-C1-3烷基、-NH-C1-3烷基、苯基、-O-苯基或吡唑基、吡咯基、吡唑基或三氮唑基任选被1、2或3个Ra取代。
进一步的，所述的R2为H、F、Cl、Br、I、OH、NH2、NO2、CN、
进一步的，所述的R4为H、F、Cl、Br、I、OH、NH2、NO2、CN或
进一步的，所述的式(I)化合物为：
其中，R1、R2、R3、R4如本发明所定义。
进一步的，所述的抗肿瘤药物增敏剂为下式(1)、(2)、(3)、(4)、(5)、(6)、(7)或(8)的化合物：
实验发现本发明所述的抗肿瘤药物增敏剂可以通过下调HIF-1α的表达，降低HIF-1α和HIF-1β的二聚化程度，从而下调一系列下游因子，如PD-L1，P-gp等。
化合物7与其他化合物相比，不仅保留了羧基部分(化合物2或3需经水解才能暴露出活性基团羧基)，而且与化合物1，4，5，6，8相比更疏水，很容易被肿瘤细胞摄取，因而具有较优的治疗效果。
本发明所述的抗肿瘤药物增敏剂可与不同比例的抗肿瘤药物联用。
所述的抗肿瘤药物增敏剂与抗肿瘤药物的质量之比为0.1-20∶1。
所述的抗肿瘤药物为环磷酰胺、5-氟尿嘧啶、雷替曲塞、阿霉素类、胞苷类、抗叶酸类、紫杉醇类、吉西他滨、铂类药物、喜树碱及其衍生物、雷公藤红素、长春新碱类或藤黄酸和分子靶向类药物。
本发明所述的肿瘤为恶性肿瘤，所述的恶性肿瘤包括血液类癌症、胃癌、食道癌、结直肠癌、乳腺癌、黑色素瘤、脑癌、胰腺癌、肺癌、膀胱癌、卵巢癌、肝癌或胆管癌等。
本发明还提供了一种药物组合物，所述的药物组合物包括治疗有效量抗肿瘤药物增敏剂和药学上可接受的载体。
所述的药学上可接受的载体为水、脂质体、聚合物胶束或无机纳米载体。
抗肿瘤药物增敏剂在被制备成纳米制剂后具有长血液循环时间、可以通过肿瘤的超通透与蓄积作用(Enhanced permeability and retention effect)在肿瘤组织的更加有效地蓄积，进一步提高其抗肿瘤效果。
本发明所述的药物组合物可通过常规口服、注射等给药方式直接给药。
本发明还提供了所述的带有抗肿瘤药物增敏剂的脂质体的制备方法，包括以下步骤：
脂质体膜的制备：将磷脂或聚乙二醇化磷脂或其混合物及抗肿瘤药物增敏剂溶于溶剂1中，4～ 60℃浓缩成膜；
水化：在制得的膜中加入去离子水或合适pH的缓冲溶液1，4～ 60℃水化12～48h；再置于透析袋中室温下透析6～ 48h。
所述的磷脂为磷脂酰胆碱、磷脂酰乙醇胺、二油酰基磷脂酰乙醇胺、胆固醇半琥珀酸酯、二硬脂酸磷脂酰乙醇胺，所述的聚乙二醇化磷脂包括酸磷脂酰乙醇胺-聚乙二醇；聚乙二醇的分子量2000～10000。
所述的合适pH的缓冲溶液1为pH为2-9的缓冲溶液。
所述的合适pH的缓冲溶液1为PBS缓冲液。
所述的溶剂1为二氯甲烷、三氯甲烷、甲醇或其混合液。
所述的溶剂1为三氯甲烷与甲醇的混合液，三氯甲烷与甲醇的体积比为1-8∶1。
所述的透析袋截留分子量为500～10000KD。
本发明还提供了载有所述的抗肿瘤药物增敏剂的胶束组合物的制备方法，包括以下步骤：
胶束膜的制备：将聚合物及抗肿瘤药物增敏剂溶于溶剂2中，4～ 60℃浓缩成膜；
水化：在制得的膜中加入去离子水或合适pH的缓冲溶液，4～60℃水化2～48h；再过滤膜；
所述的共聚物为聚乙烯醇-聚丙交酯嵌段共聚物或聚氧乙烯聚氧丙烯醚嵌段共聚物。
所述的溶剂2为二氯甲烷、三氯甲烷、四氢呋喃、乙腈或丙酮。
所述的滤膜为150-250纳米滤膜。
所述的滤膜为200纳米滤膜。
所述的合适pH的缓冲溶液2为pH为2-9的缓冲溶液。
所述的合适pH的缓冲溶液2为PBS缓冲液。
本发明的有益效果主要体现在：
本发明的式(I)化合物能通过同时抑制HIF-1α及P-gp，逆转肿瘤多要耐药，抑制PD-L1等免疫抑制分子的表达、增强机体对肿瘤的免疫反应，从而提高肿瘤的化疗与免疫治疗效果。与免疫检查点抑制剂PD-1/PD-L1抗体相比，所述N-(3-羟基吡啶-2-羰基)甘氨酸及其衍生物为结构清楚的小分子化合物，合成简便。
定义和说明
除非另有说明，本文所用的下列术语和短语旨在具有下列含义。一个特定的术语或短语在没有特别定义的情况下不应该被认为是不确定的或不清楚的，而应该按照普通的含义去理解。当本文中出现商品名时，意在指代其对应的商品或其活性成分。这里所采用的术语″药学上可接受的″，是针对那些化合物、材料、组合物和/或剂型而言。它们在可靠的医学判断的范围之内，适用于与人类和动物的组织接触使用，而没有过多的毒性、刺激性、过敏性反应或其它问题或并发症，与合理的利益/风险比相称。
术语“药学上可接受的盐”是指本发明化合物的盐，由本发明发现的具有特定取代基的化合物与相对无毒的酸或碱制备。当本发明的化合物中含有相对酸性的功能团时，可以通过在纯的溶液或合适的惰性溶剂中用足够量的碱与这类化合物的中性形式接触的方式获得碱加成盐。药学上可接受的碱加成盐包括钠、钾、钙、铵、有机胺或镁盐或类似的盐。当本发明的化合物中含有相对碱性的官能团时，可以通过在纯的溶液或合适的惰性溶剂中用足够量的酸与这类化合物的中性形式接触的方式获得酸加成盐。药学上可接受的酸加成盐的实例包括无机酸盐，所述无机酸包括例如盐酸、氢溴酸、硝酸、碳酸，碳酸氢根，磷酸、磷酸一氢根、磷酸二氢根、硫酸、硫酸氢根、氢碘酸、亚磷酸等；以及有机酸盐，所述有机酸包括如乙酸、丙酸、异丁酸、马来酸、丙二酸、苯甲酸、琥珀酸、辛二酸、反丁烯二酸、乳酸、扁桃酸、邻苯二甲酸、苯磺酸、对甲苯横酸、柠檬酸、酒石酸和甲磺酸等类似的酸；还包括氨基酸(如精氨酸等)的盐，以及如葡糖醛酸等有机酸的盐。本发明的某些特定的化合物含有碱性和酸性的官能团，从而可以被转换成任一碱或酸加成盐。
本发明的药学上可接受的盐可由含有酸根或碱基的母体化合物通过常规化学方法合成。一般情况下，这样的盐的制备方法是：在水或有机溶剂或两者的混合物中，经由游离酸或碱形式的这些化合物与化学计量的适当的碱或酸反应来制备。
除了盐的形式，本发明所提供的化合物还存在前药形式。本文所描述的化合物的前药容易地在生理条件下发生化学变化从而转化成本发明的化合物。此外，前体药物可以在体内环境中通过化学或生化方法被转换到本发明的化合物。
本发明的某些化合物可以以非溶剂化形式或者溶剂化形式存在，包括水合物形式。一般而言，溶剂化形式与非溶剂化的形式相当，都包含在本发明的范围之内。
本发明的化合物可以存在特定的几何或立体异构体形式。本发明设想所有的这类化合物，包括顺式和反式异构体、(-)-和(+)-对映体、(R)-和(S)-对映体、非对映异构体、(D)-异构体、(L)-异构体，及其外消旋混合物和其他混合物，例如对映异构体或非对映体富集的混合物，所有这些混合物都属于本发明的范围之内。烷基等取代基中可存在另外的不对称碳原子。所有这些异构体以及它们的混合物，均包括在本发明的范围之内。
当一个片段为不存在时，比如R-X中X为不存在时表示该结构实际上是R。
除非另有规定，术语“C1-20烷基”本身或者与其他术语联合分别用于表示包含1至20个碳原子的直链或支链的饱和的碳基团。所述C1-20烷基包括C1、C2、C3、C4、C5、C6、C7、C8、C9、C10、C11、C12、C13、C14、C15、C16、C17、C18、C19、C20烷基等。其可以是一价(如甲基)、二价(如亚甲基)或者多价(如次甲基)。C1-20烷基的实例包括但不限于甲基(Me)，乙基(Et)，丙基(包括n-丙基和异丙基)，丁基(包括n-丁基，异丁基，s-丁基和t-丁基)，戊基(包括n-戊基，异戊基和新戊基)、己基、庚基、辛基、壬基、癸基等。术语“C1-4烷基”的实例包括但不限于甲基(Me)，乙基(Et)，丙基(包括n-丙基和异丙基)、丁基(包括n-丁基，异丁基，s-丁基和t-丁基)等。术语“C1-3烷基”的实例包括但不限于甲基(Me)，乙基(Et)，丙基(包括n-丙基和异丙基)等除非另有规定，术语“C1-3烷基”用于表示包含1至3个碳原子的直链或支链的基团。所述C1-3烷基包括C1-3、C1-2、C1、C2、C3烷基等。其可以是一价(如甲基)、二价(如亚甲基)或者多价(如次甲基)。C1-烷基的实例包括但不限于甲基(Me)，乙基(Et)，丙基(包括n-丙基和异丙基)等。除非另有规定，本发明“烷基”任选被1-5个F、Cl、Br、I、OH、NH2、CN取代。
除非另有规定，术语“芳基”用于表示多不饱和的碳环体系，它可以是单环、双环或多环体系，其中至少一个环是芳香性的，所述的双环和多环体系中的各个环稠合在一起，其可以是单取代的或多取代的，可以是一价、二价或多价，C6-12芳基的实例包括但不限于苯基、萘基(包括1-萘基和2-萘基)。除非另有规定，本发明“芳基”任选被1-5个F、Cl、Br、I、OH、NH2、CN取代。“芳基-O-”是指经由氧键(-O-)与分子的其余部分键合的芳基。“芳基-NH-”是指经由氮键与分子的其余部分键合的芳基。
除非另有说明，术语“5-10元杂芳基”是指包含氢原子、5至9个环碳原子、一至9个选自氮、氧和硫的环杂原子和至少一个包含杂原子的芳香环的5元至12元环系基团。出于本发明的实施方案的目的，杂芳基可以为单环、双环、三环或四环环系，其可以包括稠合或桥接的环系；并且杂芳基中的氮、碳或硫原子可以任选地被氧化；氮原子可以任选地被季铵化。实例包括但不限于氮杂环庚三烯基、吖啶基、苯并咪唑基、苯并噻唑基、苯并吲哚基、苯并间二氧杂环戊烯基、苯并呋喃基、苯并噁唑基、苯并噻唑基、苯并噻二唑基、苯并[b][1，4]二氧杂环庚-5-烯基、1，4-苯并二噁烷基、苯并萘并呋喃基、苯并噁唑基、苯并间二氧杂环戊烯基、1，4-苯并二氧杂环己烯基、苯并吡喃基、苯并吡喃酮基、苯并呋喃基、苯并呋喃酮基、苯并噻吩基、苯并***基、苯并[4，6]咪唑并[1，2-a]吡啶基、咔唑基、噌啉基、二苯并呋喃基、二苯并噻吩基、呋喃基、呋喃酮基、异噻唑基、咪唑基、吲唑基、吲哚基、吲唑基、异吲哚基、吲哚啉基、异吲哚啉基、异喹啉基、中氮茚基、异噁唑基、萘啶基、噁二唑基、2-氧代吖庚因基、噁唑基、环氧乙烷基、1-氧化吡啶基、1-氧化嘧啶基、1-氧化吡嗪基、1-氧化哒嗪基、1-苯基-1H-吡咯基、吩嗪基、吩噻嗪基、吩噁嗪基、酞嗪基、喋啶基、嘌呤基、吡咯基、吡唑基、吡啶基、吡嗪基、嘧啶基、哒嗪基、喹唑啉基、喹喔啉基、喹啉基、奎宁环基、异喹啉基、四氢喹啉基、噻唑基、噻二唑基、***基、四唑基、三嗪基和噻吩基。
术语“被取代的”是指特定原子上的任意一个或多个氢原子被取代基取代，可以包括重氢和氢的变体，只要特定原子的价态是正常的并且取代后的化合物是稳定的。当取代基为氧(即＝O)时，意味着两个氢原子被取代。氧取代不会发生在芳香基上。
术语“任选被取代”是指可以被取代，也可以不被取代，除非另有规定，取代基的种类和数目在化学上可以实现的基础上可以是任意的。
当任何变量(例如R)在化合物的组成或结构中出现一次以上时，其在每一种情况下的定义都是独立的。因此，例如，如果一个基团被0-2个R所取代，则所述基团可化任选地至多被两个R所取代，并且每种情况下的R都有独立的选项。此外，取代基和/或其变体的组合只有在这样的组合会产生稳定的化合物的情况下才是被允许的。
当一个连接基团的数量为0时，比如-(CRR)0-，表示该连接基团为单键。
本发明术语“治疗有效量”意指(i)治疗或预防特定疾病、病况或障碍，(ii)减轻、改善或消除特定疾病、病况或障碍的一种或多种症状，或(iii)预防或延迟本文中所述的特定疾病、病况或障碍的一种或多种症状发作的本申请化合物的用量。构成“治疗有效量”的本申请化合物的量取决于该化合物、疾病状态及其严重性、给药方式以及待被治疗的哺乳动物的年龄而改变，但可例行性地由本领域技术人员根据其自身的知识及本公开内容而确定。
本发明术语“药物组合物”是指一种或多种本申请的化合物或其盐与药学上可接受的载体组成的混合物。药物组合物的目的是有利于对有机体给予本申请的化合物。
本发明术语“药学上可接受的载体”是指对有机体无明显刺激作用，而且不会损害该活性化合物的生物活性及性能的那些辅料。合适的辅料是本领域技术人员熟知的，例如碳水化合物、蜡、水溶性和/或水可膨胀的聚合物、亲水性或疏水性材料、明胶、油、溶剂、水、脂质体、聚合物胶束或无机纳米载体等。
本发明所使用的溶剂可经市售获得。
本发明采用下列缩略词：HIF-1α代表乏氧诱导因子-1α；PD-L1代表程序性死亡受体-配体1；IDO代表吲哚胺2，3-双加氧酶；P-gp代表P糖蛋白；DOX代表阿霉素；DMSO代表二甲亚砜；PBS代表磷酸盐缓冲液；EDTA代表乙二胺四乙酸。
本发明化合物依据本领域常规命名原则或者使用
软件命名，市售化合物采用供应商目录。
附图说明
图1为测试例1A中本发明化合物降低CT26细胞PD-L1表达的Western blot结果。
图2为测试例1A中本发明化合物降低CT26细胞PD-L1表达的Western blot定量结果。
图3为测试例1B中本发明化合物降低CT26细胞PD-L1的mRNA表达的PCR结果。
图4为测试例1C中不同浓度化合物7(ROX)降低CT26细胞PD-L1表达的流式细胞计数结果。
图5为测试例1D中化合物7(ROX)与DOX联用后增加CT26细胞免疫原性死亡的结果，并与单独DOX比较。
图6为测试例1E中化合物7(ROX)处理后小鼠巨噬细胞相关基因的表达，并与不处理的小鼠巨噬细胞比较。
图7为测试例1F中本发明化合物抑制CT26细胞犬尿氨酸生成的实验结果。
图8为测试例2A中本发明化合物与化疗药物DOX联用后在CT26细胞上的细胞毒性。
图9为测试例2A中本发明化合物的细胞毒性实验结果。
图10为测试例2A中化合物7(ROX)与化疗药物紫杉醇(PTX)联用的细胞毒性实验结果。
图11为测试例2A中化合物7(ROX)与化疗药物奥沙利铂(OXA)联用的细胞毒性实验结果。
图12为测试例2A中化合物7(ROX)与化疗药物喜树碱类药物(伊立替康，SN38)联用的细胞毒性实验结果。
图13为测试例2B中本发明化合物降低CT26细胞HIF-1α表达的结果。
图14为测试例2C中化合物7(ROX)处理CT26细胞后，细胞内吞罗丹明123(Rh123)的结果，并与未处理的细胞的比较。
图15为测试例3中化合物7(ROX)、DOX及两药联用后，对CT26荷瘤小鼠肿瘤模型的抑瘤曲线。
图16为测试例3中化合物7(ROX)、DOX及两药联用后小鼠体重曲线。
图17为测试例4中阿霉素脂质体(Doxil)和化合物7的脂质体(Roxil)联用后，对CT26荷瘤小鼠肿瘤模型的抑瘤曲线。
图18为测试例4中霉素脂质体(Doxil)和化合物7的脂质体(Roxil)联用后小鼠体重曲线。
图19为测试例5中阿霉素脂质体(Doxil)和负载化合物7的胶束(PEG-PLA-ROX)联用后，对CT26荷瘤小鼠肿瘤模型的抑瘤曲线。
图20为测试例5中阿霉素脂质体(Doxil)和负载化合物7的胶束(PEG-PLA-ROX)联用后小鼠体重曲线。
具体实施方式
下面通过实施例对本发明进行详细阐述，下述说明仅为解释本发明，并不对其内容进行限定。本发明化合物可以通过本领域技术人员熟知的多种合成方法来制备，包括下面列举的具体实施方式、其与其它化合物合成方法的结合所形成的实施方式以及本领域技术人员所熟知的等同替换方式，也可以可经市售获得。优选的实施方式包括但不限于本发明的实施例。对本领域技术人员而言，在不脱离本发明精神和范围的情况下针对本发明具体实施方式进行各种变化和改进是显而易见的。
实施例1：N-(3-羟基吡啶-2-羰基)甘氨酸的酯化衍生物的制备路线如下。
以化合物(2)为例子。
化合物(1)(200mg，1.02mm0l)溶于20mL干燥的N，N二甲基甲酰胺，加入油醇(329mg，1.22mmol)和4-二甲氨基吡啶(6.23mg，0.05mmol)。N2保护并冰浴下滴加二环己基碳二亚胺(252mg，1.22mmol)，搅拌1h后撤去冰浴并继续反应过夜。反应结束后，减压旋蒸除去溶剂，用硅胶柱和流动相为正己烷∶乙酸乙酯＝5∶1纯化得白色固体化合物(2)，产率为86.9％。Formula：[C26H45N3O3]+，Calc.448.33，found 448.23。
实施例2：N-(3-羟基吡啶-2-羰基)甘氨酸的酰胺化衍生物的制备路线如下。
以化合物(3)为例子。
化合物(1)(200mg，1.02mmol)溶于20mL干燥的N，N二甲基甲酰胺，加入1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(603mg，3.06mmol)、1-羟基苯并***(207mg，1.53mmol)和油胺(328mg，1.23mmol)，N2保护并冰浴下滴入N，N-二异丙基乙胺(527mg，4.08mmol)，搅拌1h后撤去冰浴并继续反应过夜。反应结束后，减压旋蒸除去大部分溶剂，乙酸乙酯复溶，接着用1N盐酸和饱和食盐水洗涤，干燥浓缩后用正己烷∶乙酸乙酯＝3∶1为流动相过柱纯化，干燥得淡黄色固体化合物(3)，产率为91.2％。Formula：[C26H45N3O3]+，Calc.447.35，found 447.15。
本发明的化合物可参考文献(Dynamic combinatorial mass spectrometryleads to inhibitors of a2-oxoglutarate-dependent nucleic aciddemethylase.Journal of Medicinal Chemistry，2012，55(5)：2173)制备，也可以可经市售(本发明使用的小化合物来源于MedChemExpress China)获得。
测试例1：本发明化合物作为免疫增敏剂。
配置方法：实施例1及实施例2中所得的本发明化合物的DMSO溶液可以直接用于细胞实验中。
测试例1A：Western blot技术检测本发明化合物降低肿瘤细胞PD-L1的表达。
以每孔2×104个CT26细胞种于6孔板中，置于37℃恒温培养箱。待细胞贴壁后，分别加入化合物1～ 8的DMSO溶液(5μM)，继续孵育48h。随后弃去培养基，用预冷的PBS润洗细胞三遍并弃去洗液，每孔加入0.2mL含蛋白酶抑制剂的细胞裂解液，置于冰上裂解30min。
裂解完成后，用细胞刮刀将裂解液及细胞碎片刮至培养皿一侧，并用移液枪将裂解液转移至1.5mL Ep管中，于4℃离心(12000rpm/5min)后收集上清，并测定其蛋白浓度。
用RIPA裂解液将蛋白样品稀释至一定浓度，加入5×SDS上样缓冲液至蛋白量1μg/μL，置于95℃金属浴上孵育5min，冷却至室温后上样至制备好的SDS-PAGE电泳胶中(浓缩胶为5％，分离胶为12％)。用90V电压将蛋白跑至浓缩胶底部成一条直线后调整电压为125V，待溴酚蓝跑出后终止电泳。
随后将蛋白转移至硝酸纤维膜上，电压为80V，转膜时间90min。结束后将膜置于5％的脱脂牛奶中于室温封闭一小时。用TBST缓冲液洗膜三次后分别加相应的一抗(anti-PD-L1，1∶2000；anti-GAPDH，1∶10000)，4℃孵育过夜。用TBST缓冲液洗膜三次后加入辣根过氧化酶标记的二抗，室温下孵育1h。充分洗膜后进行化学发光显色，并用化学发光成像仪拍照。
结果如图1～ 2所示，本发明化合物1～ 8可以降低肿瘤细胞PD-L1的表达，其中以化合物6，7和8最优。证明本发明式(I)化合物可以降低肿瘤细胞PD-L1的表达。
测试例1B：qPCR技术检测本发明化合物降低肿瘤细胞PD-L1的mRNA表达。
以每孔2×105个CT26细胞种于6孔板中，置于37℃恒温培养箱。待细胞贴壁后，分别加入本发明化合物的DMSO溶液(5μM)，继续孵育48h。裂解并提取总RNA，进行反转录和PCR实验，检测CT26细胞PD-L1的RNA水平，以GAPDH基因为内参。
测试结果如图3所示，加入本发明化合物后PD-L1的mRNA表达水平显著降低，证明本发明化合物可以降低肿瘤细胞PD-L1的mRNA表达，其中以化合物6，7和8最优。
测试例1C：流式细胞仪检测本发明化合物降低肿瘤细胞PD-L1的表达。
将CT26细胞以每孔2×104个种植于6孔板中。待细胞贴壁后，分别加入本发明化合物的DMSO溶液(2.5μM，5μM，10μM)，继续孵育24h。弃掉培养基，用PBS润洗细胞3遍，每孔加含EDTA的胰蛋白酶0.2mL。将消化后的细胞收集于流式管中，离心去除上清，用含5％山羊血清的PBS重悬细胞，并加入anti-mouse PD-L1一抗(1μg/1×106个细胞)，于4℃孵育30min后，用PBS洗三次，再加入等量APC标记的山羊抗兔二抗，继续孵育30min后，用PBS清洗3次，上机进行流式检测。以化合物7为例展示结果。
结果如图4所示，灰色区域的积分值代表PD-L1表达率，空白组的PD-L1表达率为32.7％；2.5μM化合物7组的PD-L1表达率为24％，5μM化合物7组的PD-L1表达率为20.8％，10μM化合物7组的PD-L1表达率为18.8％。化合物7可以显著降低肿瘤细胞PD-L1的表达，并呈现浓度依赖。
测试例1D：本发明化合物增强药物引起的肿瘤细胞的免疫原性死亡。
CT26细胞铺于共聚焦培养皿中，过夜贴壁后分别加入不同的药物处理组，继续孵育24h。弃掉培养基，用PBS润洗细胞3遍，4％多聚甲醛固定10min，更换PBS润洗3次，每次3min，加入3％BSA溶液于37℃封闭30min，吸水纸吸掉封闭液，每孔加200μL钙网蛋白抗体(FITC-anti-CRT，1∶200)，常温下避光孵育1h，继续用PBS润洗细胞3次，每次3min，随后向每皿中加入DAPI染液，避光孵育5min，PBS清洗三次后于激光共聚焦显微镜下观察。
以阿霉素(DOX)与化合物7联用展示结果，如图5所示，化合物7可以使阿霉素诱导CT26肿瘤细胞表达更多的钙网蛋白，表明产生更强的免疫原性死亡。
测试例1E：本发明化合物促进巨噬细胞由M2向M1的极化。
小鼠巨噬细胞株Raw264.7接种于24孔板中，12小时细胞贴壁后，用含IL-4(40ng/mL)的培养基继续培养细胞一天，诱导其分化为M2型巨噬细胞(TAM2)。随后向TAM2中加入不同组的本发明化合物的DMSO溶液(5μM)，处理24h后收集细胞，裂解并提取总RNA，进行反转录和PCR实验，检测M2型巨噬细胞特异性蛋白arg1及M1型巨噬细胞特异性蛋白Nos2的RNA水平，以hprt基因为内参。
以化合物7为例展示结果，如图6所示，与未经本发明化合物7处理的TAM2相比，加入化合物7后arg1显著降低，且Nos2显著升高，证明本发明化合物可以促进巨噬细胞由M2向M1的极化，将促肿瘤生长的M2型巨噬细胞转成肿瘤抑制型的M1型巨噬细胞，因而有利于提高肿瘤治疗效果。
测试例1F：本发明化合物抑制吲哚胺2，3-双加氧酶的表达。
将CT26细胞以5×104个/孔种植于12孔板，每孔加入2mL培养基(含有100μM色氨酸)。培养一天后加入一定浓度梯度的本发明化合物的DMSO溶液，再加入0.1μg/mL INF-γ以诱导1DO的表达。孵育72h后，取200μL上清液加入10μL30％三氟乙酸溶液沉淀蛋白。用HPLC检测上清溶液中犬尿氨酸的含量，每个孔重复三次。
如图7所示，结果表明本发明化合物可以抑制色氨酸向犬尿氨酸转变，表明本发明化合物能够抑制吲哚胺2，3-双加氧酶的表达。因此，本发明化合物可以通过抑制吲哚胺2，3-双加氧酶的表达，增强癌症免疫治疗效果。
测试例2：本发明化合物作为化疗增敏剂的应用。
配置方法：实施例1及实施例2中所得的本发明化合物的DMSO溶液可以直接用于细胞实验中。
测试例2A：本发明化合物与多种化疗药物联用的细胞毒性研究。
将CT26细胞(MC38细胞、4T1细胞、B16F10细胞、HePal-6细胞、H22细胞、LLC细胞、MB49细胞、P388细胞、C6细胞、BXPC-3细胞、Hela细胞、MDA-MB-231细胞、A2780细胞、PC3细胞、HepG2细胞、HGC-27细胞)以5000个/孔培养于96孔板中，每孔加入100μL培养基，于5％CO2浓度和95％湿度的37℃恒温培养箱中培养24h。向每个孔加入100μL不同浓度的药物(DOX：0.01-10μg/mL；PTX：0.01-50μg/mL；Cela：0.05-1μg/mL；增敏剂为5μg/mL)，空白组加入100μL的培养基溶液。继续培养48h后，于1100rpm离心6min后弃去每个孔中的培养基，加入100μL的MTT工作液，继续培养3h。其后于3300rpm离心5min，弃尽每孔中的MTT培养液，加入100μL的DMSO，震荡5min，使每孔中的结晶全部溶解。最终用酶标仪测试样品在562nm处的吸光度。每一组数据均为同一种样品三次独立实验的平均值。测试结果如图8～12所示。
图8显示与单独使用化疗药物相比，本发明化合物与化疗药物联用可以极大地降低细胞地生存率，其中以化合物7效果最优。
图9显示在0.1-10μg/mL，本发明化合物不具有明显的细胞毒性。
图10～12显示本发明化合物7可以增加表阿霉素(DOX)、紫杉醇(PTX)、奥沙利铂(OXA)或喜树碱类药物(伊立替康，SN38)等对CT26细胞的毒性。
表1为化合物7与化疗药物DOX联用在多种细胞系上的细胞毒性实验结果。结果显示化合物7与DOX联用可以极大地降低多种肿瘤细胞的生存率。
表1
表2为化合物7与多种化疗药物联用在CT26细胞系上的细胞毒性实验结果。结果显示化合物7可以增加多种化疗药物的对CT26细胞的毒性。
表2
测试例2B：流式细胞仪检测本发明化合物降低肿瘤细胞HIF-1α的表达。
以每孔2×104个的密度将CT26细胞均匀地铺于6孔板中。待细胞贴壁后，分别加不同的本发明化合物的DMSO溶液(5μM)，继续孵育24h。弃掉培养基，用PBS润洗细胞3遍，每孔加含EDTA的胰蛋白酶0.2mL。将消化后的细胞收集于流式管中，离心去除上清，用含5％山羊血清的PBS重悬细胞，并加入FITC anti-mouse HIF-1α抗体(1μg/1×106个细胞)于4℃孵育30min后，PBS洗三次，上机进行流式检测。
结果如图13所示，与空白对照相比，N-(3-羟基吡啶-2-羰基)甘氨酸及其衍生物可以显著降低肿瘤细胞HIF-1α的表达，其中以化合物6，7和8效果最优，5μM时化合物7可降低45％的HIF-1α。
测试例2C：本发明化合物增强罗丹明123(Rh123)入肿瘤细胞的能力。
Rh123为多药耐药蛋白P-gp的底物，P-gp表达降低后可降低Rh123的细胞外排，增加其细胞内的含量，因此可用于测定细胞的P-gp蛋白的活性。将CT26细胞按1×104/孔的密度种于共聚焦成像皿中，并将细胞置于37℃恒温培养箱培养24h。随后每孔换成新鲜培养基，并加入Rh123溶液(1μM)及本发明化合物7的DMSO溶液(1μM)，孵育6h后用共聚焦显微镜观察Rh123的细胞内的情况。Rh123的激发波长为488nm，发射波长为500至550nm。
结果如图14所示，加入化合物7后能够显著增加Rh123的细胞内浓度，证明其可以通过抑制P-gp、减少对Rh123的外排。
测试例3：本发明化合物增强药物的体内抑瘤活性。
(1)配置方法
以化合物7为例，取20mg化合物7溶于0.5mL DMSO，加入0.5mL聚氧乙烯蓖麻油、吐温80或聚乙二醇500(本发明使用聚氧乙烯蓖麻油)，涡旋至混合均匀，将上述溶液加入到9mL PBS中，混匀即得化合物7的注射液。该注射液可在4℃保存6个月以上，不会有固体粉末析出。
(2)抑瘤实验
考察化合物7与化疗药物联用(阿霉素、紫杉醇、吉西他滨、奥沙利铂、喜树碱衍生物、伊立替康、雷公藤红素、藤黄酸等)对CT26鼠结肠癌的肿瘤抑制作用。Balb/c白鼠皮下接种1×106CT26肿瘤细胞，待肿瘤长至约80mm3后开始每隔两天(Day0，Day2，Day4)进行尾静脉注射。以化合物7与盐酸阿霉素联用为例，分别为空白对照组、化合物7组、盐酸阿霉素组、化合物7+盐酸阿霉素组(D1R1：3mg/kg DOX+5mg/kg化合物7；D1R2：3mg/kg DOX+10mg/kg化合物7；D1R3：5mg/kg DOX+5mg/kg化合物7；D1R4：DOX 5mg/kg+10mg/kg化合物7；)。给药结束后继续观察白鼠12天。
图15所示结果表明，同单独使用化合物7或盐酸阿霉素对比，两者联用治疗组的肿瘤体积呈缩小趋势，停药后肿瘤没有增长，保持不变。说明化合物7与盐酸阿霉素联用表现出更显著的抗癌活性，而且治疗后具有一定的记忆性。同时，化合物7可使其他抗肿瘤药物的抑瘤率提高30-70％，治疗效果在本领域处于领先水平，具有良好的应用前景。
图16显示，各组小鼠体重没有下降的现象，显示出药物的生物安全度高，毒副作用小。
测试例4：化合物7的脂质体组合物的制备及与化疗药物联用抗肿瘤活性实验。
采用薄膜分散法制备化合物7的脂质体制剂。
步骤1：首先将12.89g二油酰基磷脂酰乙醇胺(DOPE)、2.11g胆固醇半琥珀酸酯(CHEMS)、6.52g二硬脂酸磷脂酰乙醇胺-聚乙二醇2000(DSPE-mPEG2000)及5g化合物7溶于三氯甲烷(12mL)及甲醇(4mL)中，37℃水浴下减压旋干成膜。
步骤2：将步骤1所得的脂质体膜中加入5mL去离子水或缓冲溶液(本发明使用1×PBS溶液)，室温4～60℃水化24h。
步骤3：将所得溶液置于透析袋中透析8h，即得化合物7的脂质体制剂(Roxil)。
脂质体可以用不同种类的脂质原料制备，并可根据需要选择脂质原料的良溶剂，如二氯甲烷、三氯甲烷、甲醇等；本试验例选用三氯甲烷∶甲醇＝3∶1(12mL及3mL)；N-(4-羟基-1-甲基-7-苯氧基异喹啉-3-羰基)甘氨酸的浓度可根据实际需要调整。
药物制剂的尺寸表征：利用动态光散射(Dynamic Light Scattering，DLS)测定其粒度及分布，脂质制剂在水中组装成动态粒径分布为0.110，平均尺寸为105.9nm的纳米颗粒。该尺寸可用脂质体组成、制备方法等进行调节。
抗肿瘤活性实验：
Balb/c白鼠皮下注射1×106个CT26肿瘤细胞，待肿瘤长至约80mm3后开始给药，每隔两天(Day0，Day2，Day4)进行尾静脉注射。以Roxil与阿霉素脂质体联用为例，分别为空白对照组、阿霉素脂质体(Doxil，DOX给药量为5mg/kg)组、化合物7+阿霉素脂质体(Roxil+Doxil，DOX给药量为5mg/kg，ROX给药量为7.5mg/kg)，化合物7脂质体组(ROX给药量为7.5mg/kg)。给药周期结束后继续观察白鼠18天。
结果如图17所示，两种制剂联用的抗肿瘤效果明显优于单独使用阿霉素脂质体。20天后，联用组的肿瘤完全消除，而阿霉素脂质体组的肿瘤仍呈现生长趋势。图18显示，各组小鼠体重没有下降的现象，显示出药物的生物安全度高，毒副作用小。
制备成药物制剂后，化合物7与化疗药物的联用表现出显著的抗癌活性，治疗效果在本领域处于领先水平，具有良好的应用前景。
测试例5：化合物7聚合物胶束组合物的制备及其与化疗药物联用抗肿瘤活性测试。
采用薄膜蒸发法制备化合物7的聚合物胶束制剂。
步骤1：首先将化合物7(5mg)，聚乙二醇-聚乳酸(15mg)溶于三氯甲烷(10mL)，37℃水浴下减压旋干成膜。
步骤2：将去离子水或缓冲溶液(1×PBS溶液，5mL)加入步骤1的薄膜中，室温水化12小时。
步骤3：将步骤2所得的胶束溶液过200目滤膜，即得化合物7的聚合物胶束制剂(PEG-PLA-ROX，载药率为95％)。
胶束可以用不同种类的聚合物原料制备，并可根据需要选择胶束原料的良溶剂，如二氯甲烷、三氯甲烷、四氢呋喃、乙腈、丙酮等；本试验例选用三氯甲烷；步骤1中的原料比例可根据试剂需要调整。
药物制剂的尺寸表征：利用动态光散射(Dynamic Light Scattering，DLS)测定其粒度及分布，胶束制剂在水中组装成动态粒径分布为0.121，平均尺寸为71.9nm的纳米颗粒。该尺寸可用聚合物组成、制备方法等进行调节。
抗肿瘤活性实验：
Balb/c白鼠皮下注射1×106个CT26肿瘤细胞，待肿瘤长至约80mm3后开始给药，每隔两天(Day0，Day2，Day4)进行尾静脉注射。以PEG-PLA-ROX与阿霉素脂质体联用为例，分别为空白对照组、阿霉素脂质体(Doxil，DOX给药量为5mg/kg)组、PEG-PLA-ROX+阿霉素脂质体(PEG-PLA-ROX+Doxil，DOX给药量为5mg/kg，ROX给药量为5mg/kg)；PEG-PLA-ROX组(ROX给药量为5mg/kg)。给药周期结束后继续观察白鼠18天。
结果如图19所示，图19显示两种制剂联用的抗肿瘤效果明显优于单独使用阿霉素脂质体。22天后，联用组的肿瘤完全消除，而阿霉素脂质体组的肿瘤仍呈现生长趋势。图20显示联用组小鼠体重没有下降的现象，显示出药物的生物安全度高，毒副作用小。
制备成药物制剂后，PEG-PLA-ROX与化疗药物的联用表现出显著的抗癌活性，治疗效果在本领域处于领先水平，具有良好的应用前景。
Claims (6)
1.一种N-(3-羟基吡啶-2-羰基)甘氨酸及其衍生物在制备抗肿瘤药物增敏剂中的应用，其特征在于，
所述的N-(3-羟基吡啶-2-羰基)甘氨酸及其衍生物为下式(1)、(2)、(3)、(4)、(5)、(6)、(7)或(8)的化合物：
2.根据权利要求1所述的应用，其特征在于，所述的抗肿瘤药物增敏剂与抗肿瘤药物联用。
3.根据权利要求2所述的应用，其特征在于，抗肿瘤药物增敏剂与抗肿瘤药物的质量比为0.1～20：1。
4.根据权利要求1所述的应用，其特征在于，所述的抗肿瘤药物增敏剂制成药物组合物，所述的药物组合物包括治疗有效量抗肿瘤药物增敏剂和药学上可接受的载体。
5.根据权利要求1所述的应用，其特征在于，所述的抗肿瘤药物增敏剂制成药物脂质体组合物，包括以下步骤：
脂质体膜的制备：将磷脂或聚乙二醇化磷脂或其混合物及抗肿瘤药物增敏剂溶于溶剂1中，30～60℃浓缩成膜；
水化：在制得的膜中加入去离子水或合适pH的缓冲溶液1，4～60℃水化12～48h；再置于透析袋中室温下透析6～48h。
6.根据权利要求1所述的应用，其特征在于，负载所述的抗肿瘤药物增敏剂制成药物胶束组合物，包括以下步骤：
胶束膜的制备：将共聚物和抗肿瘤药物增敏剂溶于溶剂2中，4～60℃浓缩成膜；
水化：在制得的膜中加入去离子水或合适pH的缓冲溶液，4～60℃水化2～48h；再过滤膜；
所述的共聚物为聚乙烯醇-聚丙交酯嵌段共聚物或聚氧乙烯聚氧丙烯醚嵌段共聚物。
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911306631.5A CN112979541B (zh) | 2019-12-17 | 2019-12-17 | 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用 |
| US18/012,999 US20230248717A1 (en) | 2019-12-17 | 2020-10-29 | N-(3-hydroxypyridine-2-carbonyl)glycine-based antitumor drug sensitizer and application thereof |
| PCT/CN2020/124755 WO2021120874A1 (zh) | 2019-12-17 | 2020-10-29 | 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911306631.5A CN112979541B (zh) | 2019-12-17 | 2019-12-17 | 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112979541A CN112979541A (zh) | 2021-06-18 |
| CN112979541B true CN112979541B (zh) | 2022-11-11 |
Family
ID=76343730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911306631.5A Active CN112979541B (zh) | 2019-12-17 | 2019-12-17 | 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20230248717A1 (zh) |
| CN (1) | CN112979541B (zh) |
| WO (1) | WO2021120874A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202334158A (zh) | 2021-10-28 | 2023-09-01 | 香港商英矽智能科技知識產權有限公司 | 含脯胺醯羥化酶結構域之蛋白質(phd)抑制劑及其用途 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1126203A (zh) * | 1993-12-30 | 1996-07-10 | 赫彻斯特股份公司 | 取代杂环羧酰胺及其制备和药用 |
| CN1184104A (zh) * | 1996-12-04 | 1998-06-10 | 赫彻斯特股份公司 | 3－羟基吡啶－2－羧酸酰胺脂,其制备及其作为药物的应用 |
| CN1218802A (zh) * | 1997-10-20 | 1999-06-09 | 德国赫彻斯特马里奥罗塞尔有限公司 | 取代的异喹啉-3-甲酰胺类化合物,其制备方法及其作为药物的用途 |
| CN1957930A (zh) * | 2006-09-22 | 2007-05-09 | 浙江大学 | 和厚朴酚在制备肿瘤化疗增敏剂中的应用 |
| CN101506149A (zh) * | 2006-06-26 | 2009-08-12 | 宝洁公司 | 脯氨酰羟化酶抑制剂及使用方法 |
| CN107320474A (zh) * | 2017-08-02 | 2017-11-07 | 浙江大学 | 色瑞替尼在制备肿瘤化疗药物增敏剂中的应用及抗肿瘤药物组合物 |
| CN107759564A (zh) * | 2017-11-28 | 2018-03-06 | 中国药科大学 | 三氮唑吡啶甲酰甘氨酸类化合物、其法及医药用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201322733D0 (en) * | 2013-12-20 | 2014-02-05 | Isis Innovation | Chemical compounds |
| KR20190093651A (ko) * | 2016-12-13 | 2019-08-09 | 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. | ((5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐)아미노)아세트산의 신규한 결정질 형태 및 이의 제조 방법 |
| AR114886A1 (es) * | 2018-05-09 | 2020-10-28 | Akebia Therapeutics Inc | Proceso para preparar ácido 2-[[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino]acético |
| CN109593084B (zh) * | 2019-01-23 | 2021-09-28 | 中国药科大学 | 脯氨酰羟化酶小分子光敏前药及其制备方法与应用 |
-
2019
- 2019-12-17 CN CN201911306631.5A patent/CN112979541B/zh active Active
-
2020
- 2020-10-29 WO PCT/CN2020/124755 patent/WO2021120874A1/zh active Application Filing
- 2020-10-29 US US18/012,999 patent/US20230248717A1/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1126203A (zh) * | 1993-12-30 | 1996-07-10 | 赫彻斯特股份公司 | 取代杂环羧酰胺及其制备和药用 |
| CN1184104A (zh) * | 1996-12-04 | 1998-06-10 | 赫彻斯特股份公司 | 3－羟基吡啶－2－羧酸酰胺脂,其制备及其作为药物的应用 |
| CN1218802A (zh) * | 1997-10-20 | 1999-06-09 | 德国赫彻斯特马里奥罗塞尔有限公司 | 取代的异喹啉-3-甲酰胺类化合物,其制备方法及其作为药物的用途 |
| CN101506149A (zh) * | 2006-06-26 | 2009-08-12 | 宝洁公司 | 脯氨酰羟化酶抑制剂及使用方法 |
| CN1957930A (zh) * | 2006-09-22 | 2007-05-09 | 浙江大学 | 和厚朴酚在制备肿瘤化疗增敏剂中的应用 |
| CN107320474A (zh) * | 2017-08-02 | 2017-11-07 | 浙江大学 | 色瑞替尼在制备肿瘤化疗药物增敏剂中的应用及抗肿瘤药物组合物 |
| CN107759564A (zh) * | 2017-11-28 | 2018-03-06 | 中国药科大学 | 三氮唑吡啶甲酰甘氨酸类化合物、其法及医药用途 |
Non-Patent Citations (2)
| Title |
|---|
| Accessing 4-oxy-substituted isoquinolinones via C–H activation and regioselective migratory insertion with electronically biased ynol ethers;Brandon L. Coles-Taylor et al.;《Org. Biomol. Chem.》;20181024;第16卷(第44期);第8639-8646页 * |
| Inhibition of a viral prolyl hydroxylase;Gareth W. Langley et al.;《Bioorganic & Medicinal Chemistry》;20190123;第27卷;第2405-2412页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112979541A (zh) | 2021-06-18 |
| WO2021120874A1 (zh) | 2021-06-24 |
| US20230248717A1 (en) | 2023-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huang et al. | Enhanced cancer therapy through synergetic photodynamic/immune checkpoint blockade mediated by a liposomal conjugate comprised of porphyrin and IDO inhibitor | |
| TWI402270B (zh) | 作為化學輻射敏感劑之喜樹鹼衍生物 | |
| WO2017162108A1 (zh) | 一种柱芳烃类复合物、其制备方法、药物组合物和用途 | |
| US20120219568A1 (en) | Epidithiodioxopiprazines and uses thereof in treating cancer | |
| WO2016045505A1 (zh) | 一种喜树碱类磷脂化合物、其药物组合物及应用 | |
| HU229366B1 (en) | Use of esters of l-carnitine or alkanoyl l-carnitines as cationic lipids for the intracellular delivery of pharmacologically active compounds | |
| WO2020177748A1 (zh) | 季铵化修饰紫杉烷衍生物、其药物组合物和用途 | |
| WO2015117551A1 (zh) | 吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途 | |
| US10730898B2 (en) | Compound and use thereof and platinum complex and lipidosome thereof | |
| CN112979541B (zh) | 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用 | |
| JP6270823B2 (ja) | ステロール誘導体、及び形質転換した星状膠細胞に関係する疾患を治療するため、または悪性血液疾患を治療するためのその使用 | |
| Wang et al. | Endoplasmic reticulum-targeted glutathione and pH dual responsive vitamin lipid nanovesicles for tocopheryl DM1 delivery and cancer therapy | |
| CN110840844A (zh) | 生物素与葡萄糖共同修饰的乳腺癌靶向脂质体的制备和应用 | |
| CN110522923A (zh) | 果糖和rgd肽共修饰的双重靶向三阴性乳腺癌的脂质材料 | |
| CN105131039A (zh) | 一种喜树碱类磷脂化合物、其药物组合物及应用 | |
| CN112915087B (zh) | 一种基于5-羧基-8-羟基喹啉的抗肿瘤药物增敏剂及其应用 | |
| CN113082222B (zh) | 一种靶向肿瘤细胞线粒体的肽基纳米药物及其制备方法与应用 | |
| CN114788875A (zh) | 一种激活Hippo通路的超分子纳米药物及其制备方法与应用 | |
| US20150238488A1 (en) | Drug composition for treating tumors and application thereof | |
| CN115403583A (zh) | 一种靶向降解fak蛋白的化合物及其用途 | |
| JP2014515026A (ja) | アカデシン誘導体、それを含有する製剤および組成物、その治療目的での使用、ならびにその合成法 | |
| CA2518748A1 (en) | Antimicrobial agents and anticancer agents | |
| JP2002535251A (ja) | 癌治療のための新規化合物 | |
| US10123973B2 (en) | Liposome composition for cancer treatment | |
| KR20040051958A (ko) | 폴리에틸렌글리콜 결합 스핑고지질 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |